Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Open access
Bartunek, Jozef, Terzic, Andre, Davison, Beth A., Filippatos, Gerasimos S., Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G., Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M., Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L., Shochat, Michael K., Kasprzak, Jaroslaw D., Sanz-Ruiz, Ricardo, Heyndrickx, Guy R., Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez-Aviles, Francisco, Jimenez-Quevedo, Pilar, Bayes-Genis, Antoni, Hernandez-Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A., Teerlink, John R., Gersh, Bernard J., Povsic, Thomas J., Henry, Timothy D., Metra, Marco, Hajjar, Roger J., Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, Wijns, William, for the CHART Program · 2016 · European Heart Journal

Abstract

AIMS: Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. METHODS AND RESULTS: This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein-Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann-Whitney estimator 0.54, 95% confidence interval [CI] 0.47-0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients) (Mann-Whitney estimator 0.61, 95% CI 0.52-0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. CONCLUSION: The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehw543

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 31

  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200. · DOI · Paper page
  2. 10.1016/j.jacc.2010.05.011 · DOI · Paper page
  3. 10.1016/S0140-6736(14)61889-4 · DOI · Paper page
  4. 10.1038/nrcardio.2014.9 · DOI · Paper page
  5. Menasche, 2016, Stem cells for the treatment of heart failure, Curr Res Transl Med, 64, 97, 10.1016/j.retram.2016.04.003 · DOI
  6. 10.1161/CIRCRESAHA.115.304353 · DOI
  7. 10.1001/jama.2012.64751 · DOI
  8. 10.1093/eurheartj/ehu117 · DOI
  9. 10.1001/jama.2013.3527 · DOI · Paper page
  10. 10.1016/j.jacc.2013.08.724 · DOI · Paper page
  11. 10.1001/jama.2013.282909 · DOI · Paper page
  12. 10.1016/S0140-6736(16)30137-4 · DOI · Paper page
  13. Terzic, 2016, Stem cell therapy for heart failure: ensuring regenerative proficiency, Trends Cardiovasc Med, 26, 395, 10.1016/j.tcm.2016.01.003 · DOI
  14. 10.1016/j.jacc.2010.03.066 · DOI · Paper page
  15. 10.1016/j.jacc.2013.02.071 · DOI · Paper page
  16. 10.1161/CIRCINTERVENTIONS.112.000422 · doi:10.1161/circinterventions.112.000422
  17. 10.1002/ejhf.434 · DOI
  18. 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7 · DOI · Paper page
  19. 10.1093/biostatistics/kxh002 · DOI · Paper page
  20. 10.1093/eurheartj/ehv213 · DOI
  21. 10.1038/clpt.2008.295 · doi:10.1038/clpt.2008.295
  22. 10.1161/CIRCRESAHA.116.304386 · DOI · Paper page
  23. 10.1146/annurev.med.051508.215152 · DOI
  24. 10.1161/CIRCRESAHA.116.303614 · DOI · Paper page
  25. 10.1161/CIRCRESAHA.114.305075 · doi:10.1161/circresaha.114.305075
  26. Bax, 2004, Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis, Circulation, 110, II18, 10.1161/01.CIR.0000138195.33452.b0 · DOI
  27. 10.1016/j.ejcts.2004.12.031 · DOI · Paper page
  28. 10.1161/CIRCULATIONAHA.110.014324 · DOI · Paper page
  29. 10.1001/jama.289.19.2554 · DOI · Paper page
  30. 10.1177/1740774515609106 · DOI
  31. Terzic A, Pfenning MA, Gores GJ, Harper CM Jr. Regenerative medicine build-out. Stem Cells Transl Med 2015;4:1373–1379. · DOI

Cited by

See all 211

Metadata

Authors
Bartunek, J., Terzic, A., Davison, B. A., Filippatos, G. S., Radovanovic, S., Beleslin, B., Merkely, B., Musialek, P., Wojakowski, W., Andreka, P., Horvath, I. G., Katz, A., Dolatabadi, D., El Nakadi, B., Arandjelovic, A., Edes, I., Seferovic, P. M., Obradovic, S., Vanderheyden, M., Jagic, N., Petrov, I., Atar, S., Halabi, M., Gelev, V. L., Shochat, M. K., Kasprzak, J. D., Sanz-Ruiz, R., Heyndrickx, G. R., Nyolczas, N., Legrand, V., Guédès, A., Heyse, A., Moccetti, T., Fernandez-Aviles, F., Jimenez-Quevedo, P., Bayes-Genis, A., Hernandez-Garcia, J. M., Ribichini, F., Gruchala, M., Waldman, S. A., Teerlink, J. R., Gersh, B. J., Povsic, T. J., Henry, T. D., Metra, M., Hajjar, R. J., Tendera, M., Behfar, A., Alexandre, B., Seron, A., Stough, W. G., Sherman, W., Cotter, G., Wijns, W., & Program, F. T. C.
Venue
European Heart Journal
Published
2016-12-23
Volume
38
Issue
9
Pages
ehw543
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2564731431
Cited by
211
References
1
FWCI
17.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehw543
The paper
Bartunek, J., Terzic, A., Davison, B. A., Filippatos, G. S., Radovanovic, S., Beleslin, B., Merkely, B., Musialek, P., Wojakowski, W., Andreka, P., Horvath, I. G., Katz, A., Dolatabadi, D., El Nakadi, B., Arandjelovic, A., Edes, I., Seferovic, P. M., Obradovic, S., Vanderheyden, M., . . . Program, F. T. C. (2016). Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehw543

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.